Detalhe da pesquisa
1.
Perioperative dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin in muscle-invasive bladder cancer (VESPER): survival endpoints at 5 years in an open-label, randomised, phase 3 study.
Lancet Oncol
; 25(2): 255-264, 2024 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-38142702
2.
Atezolizumab plus cabozantinib versus cabozantinib monotherapy for patients with renal cell carcinoma after progression with previous immune checkpoint inhibitor treatment (CONTACT-03): a multicentre, randomised, open-label, phase 3 trial.
Lancet
; 402(10397): 185-195, 2023 07 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-37290461
3.
Extended Safety and Tolerability of Darolutamide for Nonmetastatic Castration-Resistant Prostate Cancer and Adverse Event Time Course in ARAMIS.
Oncologist
; 2024 Feb 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-38394384
4.
Body Mass Index, Sarcopenia, and Their Variations in Predicting Outcomes for Patients Treated with Nivolumab for Metastatic Renal Cell Carcinoma.
Oncology
; 100(2): 114-123, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-34999587
5.
Safety and efficacy of temsirolimus as second line treatment for patients with recurrent bladder cancer.
BMC Cancer
; 18(1): 194, 2018 02 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-29454321
6.
The New Combination Docetaxel, Prednisone and Curcumin in Patients with Castration-Resistant Prostate Cancer: A Pilot Phase II Study.
Oncology
; 90(2): 69-78, 2016.
Artigo
em Inglês
| MEDLINE | ID: mdl-26771576
7.
Everolimus in Metastatic Breast Cancer: Clinical Experience as a Late Treatment Line.
Oncology
; 89(6): 319-31, 2015.
Artigo
em Inglês
| MEDLINE | ID: mdl-26457979
8.
Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial.
Lancet Oncol
; 15(7): 700-12, 2014 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-24831977
9.
A Randomized, Open-label, Cross-over Phase 2 Trial of Darolutamide and Enzalutamide in Men with Asymptomatic or Mildly Symptomatic Metastatic Castrate-resistant Prostate Cancer: Patient Preference and Cognitive Function in ODENZA.
Eur Urol
; 85(3): 274-282, 2024 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-37271630
10.
Activity of Lutetium-177 Prostate-specific Membrane Antigen and Determinants of Outcomes in Patients with Metastatic Castration-resistant Prostate Cancer Previously Treated with Cabazitaxel: The PACAP Study.
Eur Urol Oncol
; 2024 Apr 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-38664139
11.
Abigene, a Prospective, Multicentric Study of Abiraterone Acetate Pharmacogenetics in Metastatic Castration-Resistant Prostate Cancer.
Pharmaceutics
; 15(2)2023 Feb 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-36839973
12.
Refining the Characterization and Outcome of Pathological Complete Responders after Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer: Lessons from the Randomized Phase III VESPER (GETUG-AFU V05) Trial.
Cancers (Basel)
; 15(6)2023 Mar 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-36980628
13.
COVID-19 Infection despite Previous Vaccination in Cancer Patients and Healthcare Workers: Results from a French Prospective Multicenter Cohort (PAPESCO-19).
Cancers (Basel)
; 15(19)2023 Sep 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-37835471
14.
Adrenal Metastases Are Associated with Poor Outcomes in Patients with Metastatic Clear Cell Renal Cell Carcinoma Treated with Nivolumab in the GETUG-AFU-26 NIVOREN Phase 2 Trial.
Eur Urol Oncol
; 2023 Oct 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-37813745
15.
COVID-19 Vaccination Campaign in Cancer Patients and Healthcare Workers-Results from a French Prospective Multicenter Cohort (PAPESCO-19).
Cancers (Basel)
; 14(22)2022 Nov 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-36428640
16.
COVID-19 Infections in Cancer Patients Were Frequently Asymptomatic: Description From a French Prospective Multicenter Cohort (PAPESCO-19).
Clin Med Insights Oncol
; 16: 11795549221090187, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-35465469
17.
Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin or Gemcitabine and Cisplatin as Perioperative Chemotherapy for Patients With Nonmetastatic Muscle-Invasive Bladder Cancer: Results of the GETUG-AFU V05 VESPER Trial.
J Clin Oncol
; 40(18): 2013-2022, 2022 06 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-35254888
18.
[Metastatic renal cell carcinoma: Management of toxicities of combinations]. / Cancer du rein métastatique : gestion des toxicités des combinaisons.
Bull Cancer
; 109(7-8): 844-861, 2022.
Artigo
em Francês
| MEDLINE | ID: mdl-35738914
19.
The GETUG SEMITEP Trial: De-escalating Chemotherapy in Good-prognosis Seminoma Based on Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography.
Eur Urol
; 82(2): 172-179, 2022 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-35599187
20.
Nivolumab plus rucaparib for metastatic castration-resistant prostate cancer: results from the phase 2 CheckMate 9KD trial.
J Immunother Cancer
; 10(8)2022 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-35977756